Hoth Therapeutics正在准备进一步的临床前研究，以验证HT-KIT的有效性和安全性。公司计划就首次人体试验与监管机构展开讨论。分析师给出的目标价在每股4至5美元之间，市场对公司前景持多方态度。欲了解Hoth更深入的财务状况和额外分析，包括7个独家ProTips，请访问 InvestingPro 。本公告基于Hoth Therapeutics的新闻稿。

Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Free Report) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 174,100 shares, a ...

Hoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumours: New York Wednesday, March 19, 2025, 18:00 Hrs [IST] Hoth ...

NEW YORK - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company valued at $8.1 million and showing a remarkable 56% gain year-to-date according to InvestingPro ...

NEW YORK - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company valued at $8.1 million and showing a remarkable 56% gain year-to-date according to InvestingPro, announced ...

After hours: March 17 at 5:53:31 PM EDT ...

The Star Wars franchise is notorious for creating some of the coolest-looking background characters in science fiction and ...

Explore Hoth Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for HOTH. Hoth Therapeutics' HT-001 shows promising interim Phase 2a trial results ...